Treatment of Disseminated MAC in Neutropenic Patients

Core Treatment Regimen

The American Thoracic Society recommends treating disseminated MAC with clarithromycin 500 mg twice daily or azithromycin 500 mg daily plus ethambutol 15 mg/kg daily as a two-drug regimen, continuing lifelong unless immune reconstitution occurs 1, 2, 3
Clarithromycin 500 mg orally twice daily is the preferred first-line agent because it clears bacteremia more rapidly than azithromycin in disseminated MAC 1, 2, 4, 3
Azithromycin 500 mg orally once daily is an acceptable alternative if clarithromycin is not tolerated 1, 2, 4, 3
Never use clarithromycin doses exceeding 500 mg twice daily—higher doses are associated with excess mortality in AIDS patients 1, 2, 3, 5
Ethambutol 15 mg/kg orally daily must be included in all disseminated MAC regimens 1, 2, 4, 3
Macrolide monotherapy is absolutely contraindicated—nearly 50% of patients develop macrolide resistance when treated with a macrolide alone 2, 4, 3

Rifabutin at 300 mg/day provided no additional clinical benefit to the clarithromycin-ethambutol two-drug regimen, though it did reduce relapse from macrolide-resistant strains 1, 2
Rifabutin at 450 mg/day showed only modest clinical benefit as a third drug 1, 2
Critically, rifabutin combined with clarithromycin causes significant drug interactions leading to arthralgias, uveitis, neutropenia, and hepatotoxicity—making it particularly problematic in neutropenic patients 1, 2, 4

Clarithromycin and ethambutol have lower hematologic toxicity profiles than rifabutin 6
Monitor for clarithromycin-related adverse effects including gastrointestinal symptoms, liver enzyme elevations, and QTc prolongation 6, 4, 3

Obtain baseline macrolide susceptibility testing—if macrolide resistance is present, the regimen must be modified to include amikacin and moxifloxacin 1, 2, 4, 3
Perform baseline ECG to assess QTc interval—contraindicate macrolides if QTc >450 ms (men) or >470 ms (women) due to risk of fatal arrhythmias 4, 3, 5
Check baseline liver function tests 3, 5

Lifelong therapy is required unless immune reconstitution occurs 1, 2, 4, 3
Discontinue therapy only when ALL three criteria are met: completion of ≥12 months of MAC treatment, asymptomatic for MAC disease, and CD4 count >100 cells/μL sustained for ≥6 months on HAART 1, 4, 3
Restart treatment if CD4 count drops below 100 cells/μL 1, 4, 3

If baseline susceptibility testing reveals macrolide resistance or resistance develops during therapy, add amikacin and moxifloxacin to the regimen 1, 6, 2, 4, 3
Continue ethambutol as part of the multidrug regimen 1, 2, 4, 3
Treatment outcomes are significantly worse with macrolide-resistant strains 3

Never use clofazimine—it is associated with excess mortality in disseminated MAC and should be completely avoided 1, 2, 4, 3
Avoid aluminum/magnesium antacids as they reduce azithromycin absorption when taken simultaneously 4, 3
Do not confuse disseminated MAC with pulmonary MAC—disseminated disease requires daily therapy, not the intermittent regimens sometimes used for pulmonary disease 3
Ensure adequate HIV control if applicable—successful treatment of disseminated MAC requires treating both the mycobacterial infection and the underlying HIV infection with antiretroviral therapy 1, 2, 3

The Centers for Disease Control and Prevention recommends clarithromycin 500 mg twice daily as an alternative macrolide that clears bacteremia more rapidly, but azithromycin has fewer drug interactions with antiretrovirals 7
The Centers for Disease Control and Prevention advises against exceeding clarithromycin 1 g/day total, as higher doses are associated with increased mortality 7
Rifabutin can be added as a third drug to reduce resistance emergence, but causes significant drug interactions when combined with clarithromycin, making it problematic in neutropenic patients 7

Azithromycin does not require dose adjustment in renal impairment because it is not metabolized by the cytochrome P450 system and is not renally eliminated to a significant degree 7

Azithromycin is strongly preferred over clarithromycin when using protease inhibitors or NNRTIs, as azithromycin metabolism is not affected by CYP450 enzymes, allowing safe use with all antiretrovirals without dose adjustments 7
Protease inhibitors increase clarithromycin levels unpredictably 7